[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Refreshgene Technology Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100526954","phase-1-safety-and-efficacy-of-rrg001-gene-therapy-in-subjects-with-neovascular-age-related-macular-degeneration-namd-100526954",false,"NCT06141460","Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)","A Phase I\u002FIIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration","Inclusion Criteria:\n\n* Subjects that are willing and able to follow study procedures.\n* Patinets ≥50 years old.\n* Clinically diagnosed with CNV secondary to nAMD.\n* BCVA of the study eye is ≥5 letters and ≤73 letters(Snellen 20\u002F800\\~20\u002F40), as well as that of the other eye ≥19 letters(Snellen 20\u002F400).\n* Responding to anti-VEGF\n\nExclusion Criteria:\n\n* Presence of any other eye diseases other than nAMD in study eye that would affect the treatment or confusing the interpretation of the study results , as judged by the investigator.\n* CNV or macular edema in the study eye secondary to any causes other than AMD.\n* Uncontrolled glaucoma.\n* Uncontrolled hypertension despite medication.\n* Pregnant or lactating women or individuals with reproductive potential who are unwilling to take effective contraception during the study period.","ALL","50 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","A Phase I\u002FIIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration",[27],"Neovascular Age-related Macular Degeneration","RECRUITING","2024-11-12",{"date":31,"type":32},"2024-11-14","ACTUAL",{"date":34,"type":32},"2023-12-12",{"date":36,"type":20},"2030-12-31",{"name":38,"class":39},"Shanghai Refreshgene Technology Co., Ltd.","INDUSTRY",""]